Atherosclerosis:上臂动脉血压差异和冠状动脉粥样硬化发病

2017-06-26 MedSci MedSci原创

双臂动脉血压差异(IABPD)增大已经证实和动脉粥样硬化发生有关,但是是否和冠状动脉疾病发生有关目前还未知。本试验旨在研究IABPD和冠状动脉粥样硬化发病的关系。我们对初次行冠状动脉造影的患者同时测量双臂血压,对血压的数据记性回顾性的研究。在冠脉造影的结果基础上,使用Gensini评分对冠状动脉硬化程度进行评估。为了调整基础血压的影响,分别计算双臂收缩压差高于平均血压百分率(cIABPDsys)、

双臂动脉血压差异(IABPD)增大已经证实和动脉粥样硬化的发生有关,但是是否和冠状动脉疾病发生有关目前还未知。本试验旨在研究IABPD和冠状动脉粥样硬化发病的关系。

我们对初次行冠状动脉造影的患者同时测量双臂血压,对血压的数据进行回顾性的研究。在冠脉造影的结果基础上,使用Gensini评分对冠状动脉硬化程度进行评估。为了调整基础血压的影响,分别计算双臂收缩压差高于平均血压百分率(cIABPDsys)、双臂舒张压差高于平均血压百分率(cIABPDdia)、平均双臂血压差异高于平均血压(cIABPDmean)作为校正过的IABPDs。

我们记录了816名患者(其中男性516名,平均年龄65.5±11.8岁)。平均Gensini评分为33.4±30.4,中位数为25。所有的clAPBDs与Gensini评分呈正相关(cIABPDsys:r=0.208,p<0.001;cIABPDdia:r=0.123,p<0.001;cIABPDmean:r= 0.120,p = 0.001)。多元回归分析表明,cIABPDsys与Gensini评分相关,独立于年龄、性别、吸烟、糖尿病高血压和血脂异常(B=0.031,p<0.001)。

血压校正过的IABPD参数与冠状动脉疾病的严重程度相关。进一步的研究应探讨的IABPD对改善冠状动脉粥样硬化疾病的管理与治疗的帮助。

原始出处:

Park SJ1, Son JW2, Park SM1, et al. Relationship between inter-arm blood pressure difference and severity of coronaryatherosclerosis. Atherosclerosis. 2017 Jun 9;263:171-176. doi: 10.1016/j.atherosclerosis.2017.06.023.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947319, encodeId=f627194e31934, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Oct 04 07:58:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944468, encodeId=58d71944468eb, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Dec 09 15:58:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708971, encodeId=62831e08971b9, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Jun 30 02:58:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364195, encodeId=9db5136419558, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 28 01:58:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215633, encodeId=4eb921563302, content=血压随时都有变化, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jun 26 14:28:52 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947319, encodeId=f627194e31934, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Oct 04 07:58:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944468, encodeId=58d71944468eb, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Dec 09 15:58:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708971, encodeId=62831e08971b9, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Jun 30 02:58:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364195, encodeId=9db5136419558, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 28 01:58:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215633, encodeId=4eb921563302, content=血压随时都有变化, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jun 26 14:28:52 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947319, encodeId=f627194e31934, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Oct 04 07:58:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944468, encodeId=58d71944468eb, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Dec 09 15:58:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708971, encodeId=62831e08971b9, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Jun 30 02:58:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364195, encodeId=9db5136419558, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 28 01:58:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215633, encodeId=4eb921563302, content=血压随时都有变化, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jun 26 14:28:52 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947319, encodeId=f627194e31934, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Oct 04 07:58:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944468, encodeId=58d71944468eb, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Dec 09 15:58:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708971, encodeId=62831e08971b9, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Jun 30 02:58:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364195, encodeId=9db5136419558, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 28 01:58:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215633, encodeId=4eb921563302, content=血压随时都有变化, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jun 26 14:28:52 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2017-06-28 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1947319, encodeId=f627194e31934, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Oct 04 07:58:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944468, encodeId=58d71944468eb, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Dec 09 15:58:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708971, encodeId=62831e08971b9, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Jun 30 02:58:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364195, encodeId=9db5136419558, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 28 01:58:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215633, encodeId=4eb921563302, content=血压随时都有变化, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jun 26 14:28:52 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2017-06-26 楠博One

    血压随时都有变化

    0

相关资讯

给自己的孩子测个血压!

近年来,我国儿童高血压患者明显增多,超重和肥胖是其主要原因之一。约有一半的儿童高血压患者伴有肥胖。由于儿童高血压常表现为血压轻中度升高,往往无明显症状,很多患儿就诊时就已经发生左心室肥厚等靶器官损害,因此对于具有高血压高危因素的儿童(如肥胖、父母患有高血压等)应注意筛查是否存在高血压。

Circulation:SBP/DBP<140/90 mmHg人群的心血管危险因素研究!

来自2000年代之前的数据表明,在收缩压和舒张压(SBP / DBP)≥140/ 90mmHg的美国成年人中发生事件心血管疾病(CVD)事件占大多数。但是随着医疗水平的提高,人群的血压呈下降趋势,并且高血压的管理也逐步在完善。

血压降到正常了,却开始头痛了……

一位高血压朋友,平时血压170-180 mmHg,没有任何不适症状。近日在医生劝导下开始服用降压药,几天后血压降到140/90mmHg左右,但却出现头痛、头晕、全身乏力。为此,患者自行停用了降压药。这是为什么?患者这样做对吗?这种做法是不正确的。很多高血压朋友平时可以没有任何症状,只是测量血压发现有高血压。然而,高血压的危害只取决于血压高低,不取决于有无症状。只要血压增高,即便没有任何不适,也会显

SCI REP:轻微卒中或TIA患者接受双抗血小板治疗的益处受血压水平的影响!

由此可见,对于SBP≥140mmHg或DBP≥90mmHg的轻微卒中或TIA患者可以从双联抗血小板治疗中得到更多好处。在入院时血压较高的患者接受双抗血小板治疗的出血风险没有增加。

JAHA:动脉硬化程度的种族差异主要是由血压水平决定的

由此可见,cf-PWV的种族差异主要是由于平均动脉压和年龄的差异所致,尽管他们不能完全解释最高cf-PWV值的女性种族和cf-PWV之间的相关性。这表明克服衰老对血管系统影响的治疗方法应该集中在血压控制上,尤其是在黑人人群中。

Circulation:多学科讨论——SPRINT研究颠覆认知 血压高低或有新标准?

SPRINT(收缩压干预试验)证实,美国处于较高的心血管疾病风险但不合并糖尿病、卒中或心衰的成人中,与收缩压(SBP)目标<140mmHg相比,<120mmHg可使全因死亡率降低27%。2017年4月,发表在《Circulation.》的一项研究量化了如美国采用SPRINT的强化血压方案的潜在获益和风险。